BMS, Kura Partnerships Illumina also announced CDx partnerships with two additional cancer drug developers. Illumina and Bristol-Myers Squibb (BMS) expanded a 2018 collaboration as BMS agreed to develop a microsatellite instability (MSI) CDx as well as a diagnostic based on Illumina's first liquid biopsy assay, TSO 500 ctDNA. Illumina could have a second cancer blood test in its portfolio: GRAIL, the test developer Illumina plans to acquire for $8 billion later this year— confirmed it expects to introduce Galleri™, a multi-cancer early detection blood test, in the second quarter. By then, GRAIL expects to present initial results from PATHFINDER, a prospective, 6,600-participant multi-site study conducted under an FDA Investigational Device Exemption application to evaluate Galleri in clinical practice.